ARTICLE | Company News
Avanir, Impax, Par Pharmaceutical neurology news
May 5, 2014 7:00 AM UTC
A judge in the U.S. District Court for the District of Delaware issued a ruling in a patent suit that provides exclusivity for Avanir's Nuedexta dextromethorphan/quinidine ( AVP-923) through August 2026. Judge Leonard Stark upheld the validity of U.S. Patent Nos. RE38,115; 7,659,282 and 8,227,484 covering Nuedexta and held that ANDAs submitted by Par and Impax infringed the patents. ...